Literature DB >> 18826258

Diverse cell signaling events modulated by perlecan.

John M Whitelock1, James Melrose, Renato V Iozzo.   

Abstract

Perlecan is a ubiquitous pericellular proteoglycan ideally placed to mediate cell signaling events controlling migration, proliferation, and differentiation. Its control of growth factor signaling usually involves interactions with the heparan sulfate chains covalently coupled to the protein core's N-terminus. However, this modular protein core also binds with relatively high affinity to a number of growth factors and surface receptors, thereby stabilizing cell-matrix links. This review will focus on perlecan-growth factor interactions and describe recent advances in our understanding of this highly conserved proteoglycan during development, cancer growth, and angiogenesis. The pro-angiogenic capacities of perlecan that involve proliferative and migratory signals in response to bound growth factors will be explored, as well as the anti-angiogenic signals resulting from interactions between the C-terminal domain known as endorepellin and integrins that control adhesion of cells to the extracellular matrix. These two somewhat diametrically opposed roles will be discussed in light of new data emerging from various fields which converge on perlecan as a key regulator of cell growth and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18826258      PMCID: PMC2605657          DOI: 10.1021/bi8013938

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  60 in total

1.  Perlecan heparan sulfate proteoglycan: a novel receptor that mediates a distinct pathway for ligand catabolism.

Authors:  I V Fuki; R V Iozzo; K J Williams
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

Review 2.  Basement membrane proteoglycans: from cellar to ceiling.

Authors:  Renato V Iozzo
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

3.  BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan.

Authors:  Eva M Gonzalez; Charles C Reed; Gregory Bix; Jian Fu; Yue Zhang; Bagavathi Gopalakrishnan; Daniel S Greenspan; Renato V Iozzo
Journal:  J Biol Chem       Date:  2004-12-09       Impact factor: 5.157

4.  A role for perlecan in the suppression of growth and invasion in fibrosarcoma cells.

Authors:  M Mathiak; C Yenisey; D S Grant; B Sharma; R V Iozzo
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

5.  VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase.

Authors:  Christopher J Robinson; Barbara Mulloy; John T Gallagher; Sally E Stringer
Journal:  J Biol Chem       Date:  2005-10-28       Impact factor: 5.157

6.  Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism.

Authors:  Gregory Bix; Remedios Castello; Michelle Burrows; Jason J Zoeller; Michelle Weech; Rex A Iozzo; Christopher Cardi; Mathew L Thakur; Christopher A Barker; Kevin Camphausen; Renato V Iozzo
Journal:  J Natl Cancer Inst       Date:  2006-11-15       Impact factor: 13.506

7.  The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases.

Authors:  J M Whitelock; A D Murdoch; R V Iozzo; P A Underwood
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

8.  Extracellular matrices of the avian ovarian follicle. Molecular characterization of chicken perlecan.

Authors:  Susanna Hummel; Andreas Osanger; Tarek M Bajari; Manimalha Balasubramani; Willi Halfter; Johannes Nimpf; Wolfgang J Schneider
Journal:  J Biol Chem       Date:  2004-03-10       Impact factor: 5.157

9.  Perlecan maintains the integrity of cartilage and some basement membranes.

Authors:  M Costell; E Gustafsson; A Aszódi; M Mörgelin; W Bloch; E Hunziker; K Addicks; R Timpl; R Fässler
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

10.  A central function for perlecan in skeletal muscle and cardiovascular development.

Authors:  Jason J Zoeller; Angela McQuillan; John Whitelock; Shiu-Ying Ho; Renato V Iozzo
Journal:  J Cell Biol       Date:  2008-04-21       Impact factor: 10.539

View more
  114 in total

1.  Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity.

Authors:  Shaoliang Li; Chisei Shimono; Naoko Norioka; Itsuko Nakano; Tetsuo Okubo; Yoshiko Yagi; Maria Hayashi; Yuya Sato; Hitomi Fujisaki; Shunji Hattori; Nobuo Sugiura; Koji Kimata; Kiyotoshi Sekiguchi
Journal:  J Biol Chem       Date:  2010-09-15       Impact factor: 5.157

2.  Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan.

Authors:  Christine Y Chuang; Megan S Lord; James Melrose; Martin D Rees; Sarah M Knox; Craig Freeman; Renato V Iozzo; John M Whitelock
Journal:  Biochemistry       Date:  2010-07-06       Impact factor: 3.162

Review 3.  Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations.

Authors:  John F Bateman; Raymond P Boot-Handford; Shireen R Lamandé
Journal:  Nat Rev Genet       Date:  2009-03       Impact factor: 53.242

4.  Superficial dermal fibroblasts enhance basement membrane and epidermal barrier formation in tissue-engineered skin: implications for treatment of skin basement membrane disorders.

Authors:  Mathew Varkey; Jie Ding; Edward E Tredget
Journal:  Tissue Eng Part A       Date:  2013-10-17       Impact factor: 3.845

Review 5.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

Review 6.  Decoding the Matrix: Instructive Roles of Proteoglycan Receptors.

Authors:  Thomas Neill; Liliana Schaefer; Renato V Iozzo
Journal:  Biochemistry       Date:  2015-07-22       Impact factor: 3.162

7.  A comparative proteomic study of nephrogenesis in intrauterine growth restriction.

Authors:  Qian Shen; Hong Xu; Li-Ming Wei; Jing Chen; Hai-Mei Liu; Wei Guo
Journal:  Pediatr Nephrol       Date:  2010-02-04       Impact factor: 3.714

8.  Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: transcriptional repression of hypoxia-inducible factor 1α and VEGFA and concurrent inhibition of nuclear factor of activated T cell 1 (NFAT1) activation.

Authors:  Atul Goyal; Chiara Poluzzi; Chris D Willis; James Smythies; Adam Shellard; Thomas Neill; Renato V Iozzo
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

9.  Role of tyrosine phosphatase SHP-1 in the mechanism of endorepellin angiostatic activity.

Authors:  Alexander Nyström; Zabeena P Shaik; Donald Gullberg; Thomas Krieg; Beate Eckes; Roy Zent; Ambra Pozzi; Renato V Iozzo
Journal:  Blood       Date:  2009-09-29       Impact factor: 22.113

10.  Myeloperoxidase-derived oxidants selectively disrupt the protein core of the heparan sulfate proteoglycan perlecan.

Authors:  Martin D Rees; John M Whitelock; Ernst Malle; Christine Y Chuang; Renato V Iozzo; Anastasia Nilasaroya; Michael J Davies
Journal:  Matrix Biol       Date:  2009-09-27       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.